PLX
Protalix BioTherapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Protalix BioTherapeutics (PLX) Stock: Buy, Sell, or Hold?
$2.96
-0.17 (-5.43%)
▼
5d:
+17.93%
30d:
+13.41%
90d:
+33.33%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (18%)
Quality Score
42/100
Position
EXTENDED
30-Day Fair Range
$2.52 – $2.80
Position: EXTENDED
Forward P/E & Valuation
59.2x
STRETCHED
vs 36.6x historical avg
Wall Street Target
$11.00
+271.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.45 / $3.14
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.96, which is considered extended relative to its 30-day fair value range of $2.52 to $2.80. From a valuation perspective, the stock is trading at a premium (Forward PE: 59.2) compared to its historical average (36.6). At these levels, the market is pricing in 17.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.45, while resistance sits at $3.14. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: PLX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+271.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.45, while resistance sits at $3.14. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: PLX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+271.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.52 -
$2.80
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
18.1%
Trading Range & Key Levels
30-Day Trading Range
$2.52 -
$2.80
Current vs Trading Range
EXTENDED
Support Level
$2.45
Resistance Level
$3.14
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range (+5.7% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 271.6% below Wall St target ($11.00)
- NEUTRAL: Trading at premium valuation - market expects 17.4% growth which is achievable
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
59.20
Wall Street Target
$11.00
(+271.6%)
Revenue Growth (YoY)
22.8%
Earnings Growth (YoY)
65.7%
Profit Margin
24.3%
Valuation Premium vs History
+17.4% premium
PE vs Historical
59.2 vs 36.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.4%
(market-implied from PE analysis)
1-Year Target
$3.48
(+17%)
2-Year Target
$4.08
(+38%)
3-Year Target
$4.79
(+62%)
3-Yr Target (if PE normalizes)
(PE: 59→37)
PE COMPRESSION
$2.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 59.2, Growth: -79.2%)
$2.16
(+-27%)
Base:
(SPY PE: 19.9, Growth: -79.2%)
$0.72
(-76%)
Bear:
(PE: 16.9, Growth: -79.2%)
$0.62
(-79%)
📈
Valuation based on Current Earnings
Trailing PE: 12.04 | Current EPS (TTM): $0.26
Bull Case
$1.72
(-42%)
Analyst growth -50.0%, PE expands to 13.2
Base Case
$1.57
(-47%)
Market implied -50.0%, PE stable at 12.0
Bear Case
$2.13
(-28%)
Severe decline -20.0%, PE contracts to 10.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share PLX Analysis
Share this live PLX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PLX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Protalix BioTherapeutics reported Q3 2026 financial results with a 23% revenue increase driven by Elelyso and Elfabrio sales. Chiesi obtained marketing authorization in Brazil for Elfabrio, and management expects to meet or exceed revenue guidance.
Key Retail Themes:
Financial Performance
Regulatory Approvals
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 11:39 PM ET
Data refreshes hourly during market hours. Next update: 12:39 AM
Data refreshes hourly during market hours. Next update: 12:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 51 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 39 SELL |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 36 SELL |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 67 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PLX Research Pages
